LoginSignup
NRX

Nurexone Biologi Stock

StockStock
ISIN: CA67059R1091
Ticker: NRX
CA67059R1091
NRX

Price

Frequently asked questions

What is Nurexone Biologi's market capitalization?

The market capitalization of Nurexone Biologi is $31.90M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Nurexone Biologi?

Nurexone Biologi's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.0796. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Nurexone Biologi's stock?

Currently, 1 analysts cover Nurexone Biologi's stock, with a consensus target price of $2.868. Analyst ratings provide insights into the stock's expected performance.

What is the EBITDA for Nurexone Biologi?

Nurexone Biologi's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$4.06M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Nurexone Biologi?

Nurexone Biologi has a free cash flow of -$4.12M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

How many employees does Nurexone Biologi have, and what sector and industry does it belong to?

Nurexone Biologi employs approximately 8 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Nurexone Biologi's shares?

The free float of Nurexone Biologi is 67.24M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $31.90M

EPS (TTM)

 -$0.0796

Free Float

 67.24M

EBITDA (TTM)

 -$4.06M

Free Cashflow (TTM)

 -$4.12M

Pricing

52W span
$0.194$0.882

Analyst Ratings

The price target is $2.868 and the stock is covered by 1 analysts.

Buy

1

Hold

0

Sell

0

Information

NurExone Biologic Inc. is a biopharmaceutical company. The Company is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. It is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The Company is developing treatment for the reversal or reduction of paralysis following spinal cord injury (SCI) using Exosomes (membrane-bound extracellular vesicles). This technology, subject to conducting clinical trials and receiving Food and Drug Administration (the FDA) approval, can be used in various conditions such as SCI, Brain Trauma Injury (BTI), and potentially other brain and neurological indications.

8

Biotechnology & Drugs

Health Care

Identifier

ISIN

CA67059R1091

Primary Ticker

NRX

Knockouts

Join the conversation
Sign upLogin